Medigene AG (0QGJ.L)
| Chiusura precedente | 2,2800 |
| Aperto | 0,0000 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,0000 - 0,0000 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 527.977 |
| Beta (5 anni mensile) | 0,89 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,4060 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Medigene Receives $3 Million Milestone Payment from 2seventy bio
Milestone payment is related to the establishment of 2seventy bio’s strategic partnership with JW TherapeuticsPayment provides further validation of Medigene’s end-to-end platform MARTINSRIED, Germany and MUNICH, Germany, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Martinsried -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focused on the development of differentiated, best-in-class T Cell Receptor engineered T cell (TCR-T) therapies, today announced that it has received a
- GlobeNewswire
Medigene Announces Strategy and Corporate Update
Company strategy focused on developing differentiated TCR-T therapies from its proprietary “end-to-end” platform to target solid tumors with high unmet needPipeline expansion and acceleration of lead candidates with aim of advancing them into clinical developmentLead program, MDG1015, a TCR-T therapy for NY-ESO-1 combined with PD1-41BB Switch Receptor technology; at CTA /IND enabling phase, with submission planned for 2H 2024Second program, MDG10xx, TCR-T therapies for yet undisclosed targets co
